Robert DiPaola

The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network

National Cancer Institute · UM1

PI · $4.3M · Ohio State University

Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics

National Cancer Institute · UM1

Contact PI · $1.7M · Rbhs -Cancer Institute of New Jersey

Targeting p62 as a More Optimal Approach to Inhibit Autophagy Using Verteporfin as a Repurposed Therapeutic in Prostate Cancer

National Cancer Institute · R01

PI · $350K · University of Kentucky

Cancer Center Support Grant

National Cancer Institute · P30

Contact PI · $26.8M · Rutgers Biomedical and Health Sciences

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Principal investigator · Terminated · Phase 2

Rutgers, The State University of New Jersey

PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802

Principal investigator · Completed

Eastern Cooperative Oncology Group

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Principal investigator · Completed · Phase 2

National Cancer Institute (NCI)

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Principal investigator · Terminated · Phase 2

Rutgers, The State University of New Jersey